64
Participants
Start Date
June 30, 2014
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
ISIS-APO(a)Rx
ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
Placebo
Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
Herlev University Hospital, Herlev
Charite - University Hospital Berlin - Campus Virchow - Hospital, Berlin
Otto-von Guericke Universitaet, Uniklinik Magdeburg, Magdeburg
Uniklinik Koeln, Zentrum fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Cologne
Chicoutimi Hospital, Chicoutimi
Clinique des Maladies Lipidiques de Quebec Inc., Québec
University of Amsterdam - Dept. of Vascular Medicine F4-109, Amsterdam
Academic Hospital Maastricht, Maastricht
Sint Franciscus Gasthuis, Rotterdam
University Medical Center Utrecht, Utrecht
Heart of England NHS Foundation Trust, Birmingham
Barlow Medical Centre, Manchester
Newcastle Upon Tyne Hospitals, Newcastle upon Tyne
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY